Get started

Financials · CBIO

Crescent Biopharma Inc. (CBIO) financials

For fiscal 2025 (ended Dec 31, 2025), Crescent Biopharma Inc. reported $10.84M of revenue and -$153.94M of net income.

Revenue, FY2025
$10.84M
Net income, FY2025
-$153.94M
Net margin
-1419.6%
Free cash flow, FY2025
-$72.45M
Cash
$171.59M
P/S
50.56
Market cap
$548.2M
Annual revenue$10.84M
FY2016FY2025
Annual net income-$153.94M
FY2016FY2025
Annual free cash flow-$72.45M
FY2016FY2025

CBIO revenue and earnings growth

CBIO revenueQ2 2026$0

QoQ
-100.0%
5Y CAGR
+1.3%
10Y CAGR
-6.0%

CBIO revenue was $0 in fiscal Q2 2026 (ended Jun 30, 2026), compared with $0 a year earlier and down 100.0% from the prior quarter. For the full fiscal 2025 it was $10.84M. Compound annual growth was +1.3% over 5 years and -6.0% over 10 years.

CBIO net incomeQ2 2026-$24.84M

CBIO net income was -$24.84M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$21.79M a year earlier. For the full fiscal 2025 it was -$153.94M, compared with -$37.88M in fiscal 2024.

CBIO free cash flowQ2 2026-$19.48M

CBIO free cash flow was -$19.48M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$16.54M a year earlier. For the full fiscal 2025 it was -$72.45M, compared with -$31.11M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$10.84M-$10.0K$75.0K$1.16M$10.16M---$18.5K
Research and development$138.09M$14.26M$20.07M$28.39M$47.49M$44.93M$47.03M$40.09M$24.10M$23.28M
Selling, general and admin$25.39M$18.25M$19.21M$19.09M$17.12M$16.74M$14.36M$11.41M$9.83M$8.65M
Operating income-$152.63M-$40.04M-$39.28M-$47.40M-$63.45M-$51.51M-$61.39M-$51.50M-$33.93M-$31.91M
Interest expense$2.19M---------
Pre-tax income-$151.94M---------
Income tax$2.00M---------
Net income-$153.94M-$37.88M-$36.90M-$46.69M-$63.43M-$51.03M-$57.89M-$48.27M-$33.28M-$31.81M
EPS, basic--$0.59-$0.58-$0.89-$1.23-$1.12-$1.34-$1.18-$1.13-$1.50
EPS, diluted--$0.59-$0.58-$0.89-$1.23-$1.12-$1.34-$1.18-$1.13-$1.50
Diluted shares-64.5M63.3M52.5M51.5M45.7M43.3M41.0M29.4M21.3M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$213.19M$34.77M$41.79M$47.87M$90.25M$137.04M$158.20M$209.92M$123.92M$40.04M
Receivables$18.00M$0--------
Current assets$236.66M$34.80M$43.79M$50.71M$90.79M$138.27M$162.53M$212.27M$127.22M$40.52M
Total assets$240.29M$35.62M$45.32M$51.81M$94.35M$142.83M$167.97M$214.84M$128.58M$42.39M
Current liabilities$36.07M$9.61M$6.84M$8.88M$11.82M$12.43M$10.95M$8.76M$8.17M$6.33M
Total liabilities$37.28M$47.10M$6.90M$8.88M$12.74M$14.61M$13.77M$9.37M$8.88M$7.09M
Shareholders' equity$203.01M-$15.48M$38.41M$42.93M$81.60M$128.22M$154.20M$205.46M$119.70M$35.30M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$71.53M-$31.10M-$34.88M-$46.46M-$57.49M-$39.24M-$51.98M-$43.33M-$29.77M-$29.73M
Capital expenditures$919.0K$10.0K$21.4K$84.2K$14.9K$68.5K$144.9K$125.6K$294.1K$704.2K
Free cash flow-$72.45M-$31.11M-$34.90M-$46.54M-$57.50M-$39.31M-$52.13M-$43.46M-$30.06M-$30.44M
Investing cash flow-$72.92M$20.0K-$21.4K-$84.2K-$14.9K-$68.5K-$144.9K-$125.6K-$294.1K-$704.2K
Financing cash flow$322.98M$5.4K$28.82M$4.16M$10.72M$18.14M$412.9K$129.45M$113.95M$23.67M
Stock-based compensation$13.30M$4.70M$3.52M$3.86M$6.09M$6.90M$6.22M$4.59M$3.76M$2.96M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY---86.7%-93.5%-88.6%-----99.9%
Operating margin-1407.5%--392752.9%-63204.4%-5470.7%-506.8%----172505.3%
Net margin-1419.6%--368994.2%-62251.7%-5469.0%-502.1%----171945.1%
Free cash flow margin-668.1%--349013.0%-62055.6%-4958.3%-386.8%----164516.0%
Return on equity-75.8%--96.1%-108.8%-77.7%-39.8%-37.5%-23.5%-27.8%-90.1%
Return on assets-64.1%-106.4%-81.4%-90.1%-67.2%-35.7%-34.5%-22.5%-25.9%-75.0%
Current ratio6.563.626.415.717.6811.1314.8424.2215.566.40

Source: XBRL data Crescent Biopharma Inc. files with the SEC, latest filing dated Jul 30, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

CBIO peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
CBIO$10.84M--$153.94M-1419.6%$548.2M
LLY$86.46B+45.5%$27.58B31.9%$1.35T
JNJ$99.33B+7.8%$16.09B16.2%$675.03B
ABBV$66.01B+10.7%$10.34B15.7%$521.41B
MRK$67.38B+4.9%$2.45B3.6%$362.83B
NVS$54.53B+8.4%$13.98B25.6%$305.91B
AZN$58.74B+8.6%$10.22B17.4%$287.63B
ABT$48.23B+10.0%$4.70B9.7%$189.28B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$181.94B

CBIO FAQ

6 questions
  • What is CBIO revenue?
    Crescent Biopharma Inc. (CBIO) reported $10.84M of revenue for fiscal 2025 (ended Dec 31, 2025).
  • Is CBIO profitable?
    No. Crescent Biopharma Inc. reported a net loss of $153.94M for fiscal 2025 (ended Dec 31, 2025).
  • How much cash and debt does CBIO have?
    Crescent Biopharma Inc. reported $171.59M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • What is CBIO free cash flow?
    Crescent Biopharma Inc. generated -$72.45M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$71.53M less capital expenditures.
  • When did CBIO last report financial results?
    The latest statements here come from Crescent Biopharma Inc.'s 10-Q filed on Jul 30, 2026, covering the period ended Jun 30, 2026.
  • Where does this CBIO financial data come from?
    Quantisnow builds these statements from the structured XBRL data Crescent Biopharma Inc. files with the SEC. It is provided for information only and is not investment advice.